Published in J Clin Oncol on September 19, 2011
Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat Genet (2012) 7.61
K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas. Acta Neuropathol (2012) 4.00
The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma. Nat Genet (2014) 3.17
The response and survival of children with recurrent diffuse intrinsic pontine glioma based on phase II study of antineoplastons A10 and AS2-1 in patients with brainstem glioma. Childs Nerv Syst (2014) 2.66
Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations. Nat Genet (2014) 2.42
Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma. Nat Genet (2014) 2.17
Paediatric and adult glioblastoma: multiform (epi)genomic culprits emerge. Nat Rev Cancer (2014) 2.10
Histone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypes. Acta Neuropathol (2015) 2.04
Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma. Nat Genet (2014) 2.02
Paediatric and adult malignant glioma: close relatives or distant cousins? Nat Rev Clin Oncol (2012) 1.58
Overcoming autopsy barriers in pediatric cancer research. Pediatr Blood Cancer (2012) 1.47
Histopathological spectrum of paediatric diffuse intrinsic pontine glioma: diagnostic and therapeutic implications. Acta Neuropathol (2014) 1.46
Diffuse intrinsic pontine glioma: poised for progress. Front Oncol (2012) 1.41
Novel oncogenic PDGFRA mutations in pediatric high-grade gliomas. Cancer Res (2013) 1.23
Targeting Wee1 for the treatment of pediatric high-grade gliomas. Neuro Oncol (2013) 1.15
Oncogenic extracellular vesicles in brain tumor progression. Front Physiol (2012) 1.15
PD-0332991, a CDK4/6 inhibitor, significantly prolongs survival in a genetically engineered mouse model of brainstem glioma. PLoS One (2013) 1.14
Children's Oncology Group's 2013 blueprint for research: central nervous system tumors. Pediatr Blood Cancer (2012) 1.14
LIN28A immunoreactivity is a potent diagnostic marker of embryonal tumor with multilayered rosettes (ETMR). Acta Neuropathol (2012) 1.12
Unique genetic and epigenetic mechanisms driving paediatric diffuse high-grade glioma. Nat Rev Cancer (2014) 1.10
Survival prediction model of children with diffuse intrinsic pontine glioma based on clinical and radiological criteria. Neuro Oncol (2014) 1.08
Feasibility, safety, and indications for surgical biopsy of intrinsic brainstem tumors in children. Childs Nerv Syst (2013) 1.03
Pediatric high-grade glioma: biologically and clinically in need of new thinking. Neuro Oncol (2017) 0.99
The Challenge of Cancer Genomics in Rare Nervous System Neoplasms: Malignant Peripheral Nerve Sheath Tumors as a Paradigm for Cross-Species Comparative Oncogenomics. Am J Pathol (2015) 0.99
Glioblastoma multiforme: a look inside its heterogeneous nature. Cancers (Basel) (2014) 0.99
EFEMP1 induces γ-secretase/Notch-mediated temozolomide resistance in glioblastoma. Oncotarget (2014) 0.96
A standardized autopsy procurement allows for the comprehensive study of DIPG biology. Oncotarget (2015) 0.94
Human pontine glioma cells can induce murine tumors. Acta Neuropathol (2014) 0.92
A high-throughput in vitro drug screen in a genetically engineered mouse model of diffuse intrinsic pontine glioma identifies BMS-754807 as a promising therapeutic agent. PLoS One (2015) 0.91
Biopsy in a series of 130 pediatric diffuse intrinsic Pontine gliomas. Childs Nerv Syst (2015) 0.90
Increased 5-hydroxymethylcytosine and decreased 5-methylcytosine are indicators of global epigenetic dysregulation in diffuse intrinsic pontine glioma. Acta Neuropathol Commun (2014) 0.89
Diffuse intrinsic pontine glioma treated with prolonged temozolomide and radiotherapy--results of a United Kingdom phase II trial (CNS 2007 04). Eur J Cancer (2013) 0.89
Phase I trial, pharmacokinetics, and pharmacodynamics of vandetanib and dasatinib in children with newly diagnosed diffuse intrinsic pontine glioma. Clin Cancer Res (2013) 0.88
Pathology, Molecular Genetics, and Epigenetics of Diffuse Intrinsic Pontine Glioma. Front Oncol (2015) 0.86
P-glycoprotein and breast cancer resistance protein restrict the brain penetration of the CDK4/6 inhibitor palbociclib. Invest New Drugs (2015) 0.85
ACVR1 mutations in DIPG: lessons learned from FOP. Cancer Res (2014) 0.84
Molecular Biology in Pediatric High-Grade Glioma: Impact on Prognosis and Treatment. Biomed Res Int (2015) 0.83
Pre-B-cell leukemia homeobox interacting protein 1 is overexpressed in astrocytoma and promotes tumor cell growth and migration. Neuro Oncol (2014) 0.83
Tumor location, but not H3.3K27M, significantly influences the blood-brain-barrier permeability in a genetic mouse model of pediatric high-grade glioma. J Neurooncol (2015) 0.83
ABCG2 and ABCB1 Limit the Efficacy of Dasatinib in a PDGF-B-Driven Brainstem Glioma Model. Mol Cancer Ther (2016) 0.83
Postnatal growth of the human pons: a morphometric and immunohistochemical analysis. J Comp Neurol (2014) 0.83
Pre-Clinical Models of Diffuse Intrinsic Pontine Glioma. Front Oncol (2015) 0.82
Pax3 expression enhances PDGF-B-induced brainstem gliomagenesis and characterizes a subset of brainstem glioma. Acta Neuropathol Commun (2014) 0.81
Molecular markers in pediatric neuro-oncology. Neuro Oncol (2012) 0.81
The genetic signatures of pediatric high-grade glioma: no longer a one-act play. Semin Radiat Oncol (2014) 0.80
B7-H3, a potential therapeutic target, is expressed in diffuse intrinsic pontine glioma. J Neurooncol (2012) 0.80
A Novel Mouse Model of Diffuse Intrinsic Pontine Glioma Initiated in Pax3-Expressing Cells. Neoplasia (2016) 0.80
Capturing the molecular and biological diversity of high-grade astrocytoma in genetically engineered mouse models. Oncotarget (2012) 0.80
Bereaved parents' intentions and suggestions about research autopsies in children with lethal brain tumors. J Pediatr (2013) 0.80
Management of high-grade gliomas in the pediatric patient: Past, present, and future. Neurooncol Pract (2014) 0.80
Molecular genetic approaches and potential new therapeutic strategies for pediatric diffuse intrinsic pontine glioma. J Clin Oncol (2011) 0.78
Inhibition of Pediatric Glioblastoma Tumor Growth by the Anti-Cancer Agent OKN-007 in Orthotopic Mouse Xenografts. PLoS One (2015) 0.77
Dual Inhibition of PI3K/AKT and MEK/ERK Pathways Induces Synergistic Antitumor Effects in Diffuse Intrinsic Pontine Glioma Cells. Transl Oncol (2017) 0.77
Pediatric gliomas as neurodevelopmental disorders. Glia (2015) 0.77
Polo-like Kinase 1 as a potential therapeutic target in Diffuse Intrinsic Pontine Glioma. BMC Cancer (2016) 0.77
Epigenetic dysregulation: a novel pathway of oncogenesis in pediatric brain tumors. Acta Neuropathol (2014) 0.76
Non-random aneuploidy specifies subgroups of pilocytic astrocytoma and correlates with older age. Oncotarget (2015) 0.76
Toxicity evaluation of prolonged convection-enhanced delivery of small-molecule kinase inhibitors in naïve rat brainstem. Childs Nerv Syst (2014) 0.76
A preclinical study demonstrating the efficacy of nilotinib in inhibiting the growth of pediatric high-grade glioma. J Neurooncol (2015) 0.76
Convection-Enhanced Delivery for Diffuse Intrinsic Pontine Glioma Treatment. Curr Neuropharmacol (2017) 0.76
Re-Examining the Need for Tissue Diagnosis in Pediatric Diffuse Intrinsic Pontine Gliomas: A Review. Curr Neuropharmacol (2017) 0.75
Diffuse Intrinsic Pontine Glioma: New Pathophysiological Insights and Emerging Therapeutic Targets. Curr Neuropharmacol (2017) 0.75
Genomic Insights into Diffuse Intrinsic Pontine Glioma. Front Oncol (2017) 0.75
Bioinformatics analysis of the molecular mechanism of diffuse intrinsic pontine glioma. Oncol Lett (2016) 0.75
Common mutations in ALK2/ACVR1, a multi-faceted receptor, have roles in distinct pediatric musculoskeletal and neural orphan disorders. Cytokine Growth Factor Rev (2015) 0.75
Effect of time from diagnosis to start of radiotherapy on children with diffuse intrinsic pontine glioma. Pediatr Blood Cancer (2014) 0.75
Pediatric Brain Tumors: Current Knowledge and Therapeutic Opportunities. J Pediatr Hematol Oncol (2016) 0.75
BMI-1 is a potential therapeutic target in diffuse intrinsic pontine glioma. Oncotarget (2017) 0.75
Toxicity evaluation of convection-enhanced delivery of small-molecule kinase inhibitors in naïve mouse brainstem. Childs Nerv Syst (2015) 0.75
Integrated Molecular Meta-Analysis of 1,000 Pediatric High-Grade and Diffuse Intrinsic Pontine Glioma. Cancer Cell (2017) 0.75
Distinct molecular profile of diffuse cerebellar gliomas. Acta Neuropathol (2017) 0.75
Arginine auxotrophic gene signature in paediatric sarcomas and brain tumours provides a viable target for arginine depletion therapies. Oncotarget (2017) 0.75
Novel drugs in pediatric gliomas. Oncol Lett (2017) 0.75
New in vivo avatars of diffuse intrinsic pontine gliomas (DIPG) from stereotactic biopsies performed at diagnosis. Oncotarget (2017) 0.75
Glioblastoma spheroids produce infiltrative gliomas in the rat brainstem. Childs Nerv Syst (2017) 0.75
Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature (2008) 75.40
An integrated genomic analysis of human glioblastoma multiforme. Science (2008) 51.36
Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell (2006) 21.66
Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci U S A (2007) 18.83
Role of platelet-derived growth factors in physiology and medicine. Genes Dev (2008) 8.89
Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res (2008) 6.44
Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. J Clin Oncol (2008) 6.41
Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease. J Clin Oncol (2010) 4.94
Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov (2007) 4.27
Diffuse brainstem glioma in children: critical review of clinical trials. Lancet Oncol (2006) 3.68
Stereotactic biopsy of diffuse pontine lesions in children. J Neurosurg (2007) 3.66
Whole-genome profiling of pediatric diffuse intrinsic pontine gliomas highlights platelet-derived growth factor receptor alpha and poly (ADP-ribose) polymerase as potential therapeutic targets. J Clin Oncol (2010) 3.51
Activation of the ERK/MAPK pathway: a signature genetic defect in posterior fossa pilocytic astrocytomas. J Pathol (2009) 3.32
Distinct genetic signatures among pilocytic astrocytomas relate to their brain region origin. Cancer Res (2007) 3.05
Duplication of 7q34 in pediatric low-grade astrocytomas detected by high-density single-nucleotide polymorphism-based genotype arrays results in a novel BRAF fusion gene. Brain Pathol (2008) 2.61
Supratentorial high-grade astrocytoma and diffuse brainstem glioma: two challenges for the pediatric oncologist. Oncologist (2004) 2.45
Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts. Cancer Res (2010) 2.41
Frequent gains at chromosome 7q34 involving BRAF in pilocytic astrocytoma. J Neuropathol Exp Neurol (2008) 2.40
A distinct spectrum of copy number aberrations in pediatric high-grade gliomas. Clin Cancer Res (2010) 2.37
Targeting the HGF/Met signalling pathway in cancer. Eur J Cancer (2010) 2.20
Genome-wide profiling using single-nucleotide polymorphism arrays identifies novel chromosomal imbalances in pediatric glioblastomas. Neuro Oncol (2009) 2.04
The role of the IGF system in cancer: from basic to clinical studies and clinical applications. Oncology (2002) 2.03
Homozygous loss of ADAM3A revealed by genome-wide analysis of pediatric high-grade glioma and diffuse intrinsic pontine gliomas. Neuro Oncol (2010) 2.01
Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a Pediatric Brain Tumor Consortium report. Neuro Oncol (2007) 1.84
EWS/FLI-1 induces rapid onset of myeloid/erythroid leukemia in mice. Mol Cell Biol (2007) 1.72
ERBB1 is amplified and overexpressed in high-grade diffusely infiltrative pediatric brain stem glioma. Clin Cancer Res (2003) 1.71
MGMT-independent temozolomide resistance in pediatric glioblastoma cells associated with a PI3-kinase-mediated HOX/stem cell gene signature. Cancer Res (2010) 1.40
Prospective collection of tissue samples at autopsy in children with diffuse intrinsic pontine glioma. Cancer (2010) 1.30
Hoxa2 and Hoxb2 control dorsoventral patterns of neuronal development in the rostral hindbrain. Neuron (1999) 1.26
Innovative Therapies for Children with Cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumors. Neuro Oncol (2010) 1.22
Molecular genetics of pediatric brain stem gliomas. Application of PCR techniques to small and archival brain tumor specimens. J Neuropathol Exp Neurol (1993) 1.22
Neuronal defects in the hindbrain of Hoxa1, Hoxb1 and Hoxb2 mutants reflect regulatory interactions among these Hox genes. Development (2003) 1.19
Phase I trial of tipifarnib in children with newly diagnosed intrinsic diffuse brainstem glioma. Neuro Oncol (2008) 1.15
A phase I and biology study of gefitinib and radiation in children with newly diagnosed brain stem gliomas or supratentorial malignant gliomas. Eur J Cancer (2010) 1.09
Development of inhibitors of the IGF-IR/PI3K/Akt/mTOR pathway. Rev Recent Clin Trials (2010) 1.02
Combined targeted therapies in non-small cell lung cancer: a winner strategy? Curr Opin Oncol (2007) 0.93
p53 gene mutations in pontine gliomas of juvenile onset. Biochem Biophys Res Commun (1993) 0.92
Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature (2007) 75.09
Distinct and predictive chromatin signatures of transcriptional promoters and enhancers in the human genome. Nat Genet (2007) 32.41
A high-resolution map of active promoters in the human genome. Nature (2005) 24.35
Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature (2002) 15.36
A perivascular niche for brain tumor stem cells. Cancer Cell (2007) 11.55
Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat Genet (2012) 7.61
A global transcriptional regulatory role for c-Myc in Burkitt's lymphoma cells. Proc Natl Acad Sci U S A (2003) 7.30
Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol (2011) 6.67
Ethics consultation in pediatrics: long-term experience from a pediatric oncology center. Am J Bioeth (2015) 6.54
Medulloblastoma growth inhibition by hedgehog pathway blockade. Science (2002) 6.53
Pten regulates neuronal arborization and social interaction in mice. Neuron (2006) 6.11
Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. J Clin Oncol (2006) 5.96
Subtypes of medulloblastoma have distinct developmental origins. Nature (2010) 5.94
Prominin 1 marks intestinal stem cells that are susceptible to neoplastic transformation. Nature (2008) 5.59
Radial glia cells are candidate stem cells of ependymoma. Cancer Cell (2005) 5.21
Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease. J Clin Oncol (2010) 4.94
PTEN and the PI3-kinase pathway in cancer. Annu Rev Pathol (2009) 4.83
Novel mutations target distinct subgroups of medulloblastoma. Nature (2012) 4.82
Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol (2006) 4.72
Multiple recurrent genetic events converge on control of histone lysine methylation in medulloblastoma. Nat Genet (2009) 4.52
Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. J Clin Oncol (2010) 4.48
Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature (2012) 4.13
Regional and cellular gene expression changes in human Huntington's disease brain. Hum Mol Genet (2006) 3.91
Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. Acta Neuropathol (2012) 3.88
Cross-species genomics matches driver mutations and cell compartments to model ependymoma. Nature (2010) 3.70
Direct isolation and identification of promoters in the human genome. Genome Res (2005) 3.68
Late neurocognitive sequelae in survivors of brain tumours in childhood. Lancet Oncol (2004) 3.56
Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas. Nat Genet (2013) 3.51
Primary postoperative chemotherapy without radiotherapy for intracranial ependymoma in children: the UKCCSG/SIOP prospective study. Lancet Oncol (2007) 3.47
The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat Genet (2013) 3.43
The origins of medulloblastoma subtypes. Annu Rev Pathol (2008) 3.36
The SmoA1 mouse model reveals that notch signaling is critical for the growth and survival of sonic hedgehog-induced medulloblastomas. Cancer Res (2004) 3.33
Activation of the ERK/MAPK pathway: a signature genetic defect in posterior fossa pilocytic astrocytomas. J Pathol (2009) 3.32
Tumor paint: a chlorotoxin:Cy5.5 bioconjugate for intraoperative visualization of cancer foci. Cancer Res (2007) 3.25
International Society Of Neuropathology--Haarlem consensus guidelines for nervous system tumor classification and grading. Brain Pathol (2014) 3.21
Identification of CD15 as a marker for tumor-propagating cells in a mouse model of medulloblastoma. Cancer Cell (2009) 3.11
The miR-17/92 polycistron is up-regulated in sonic hedgehog-driven medulloblastomas and induced by N-myc in sonic hedgehog-treated cerebellar neural precursors. Cancer Res (2009) 3.03
Cooperativity within and among Pten, p53, and Rb pathways induces high-grade astrocytoma in adult brain. Cancer Cell (2011) 2.87
Pten loss causes hypertrophy and increased proliferation of astrocytes in vivo. Cancer Res (2004) 2.75
Dual and opposing roles of primary cilia in medulloblastoma development. Nat Med (2009) 2.73
The miR-17~92 cluster collaborates with the Sonic Hedgehog pathway in medulloblastoma. Proc Natl Acad Sci U S A (2009) 2.72
mTor is required for hypertrophy of Pten-deficient neuronal soma in vivo. Proc Natl Acad Sci U S A (2003) 2.68
Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage. Hum Mol Genet (2007) 2.54
Supratentorial high-grade astrocytoma and diffuse brainstem glioma: two challenges for the pediatric oncologist. Oncologist (2004) 2.45
The Pharmacogenomics Research Network Translational Pharmacogenetics Program: overcoming challenges of real-world implementation. Clin Pharmacol Ther (2013) 2.39
Wnt/Wingless pathway activation and chromosome 6 loss characterize a distinct molecular sub-group of medulloblastomas associated with a favorable prognosis. Cell Cycle (2006) 2.37
A distinct spectrum of copy number aberrations in pediatric high-grade gliomas. Clin Cancer Res (2010) 2.37
Markers of survival and metastatic potential in childhood CNS primitive neuro-ectodermal brain tumours: an integrative genomic analysis. Lancet Oncol (2012) 2.34
Neurocognitive consequences of risk-adapted therapy for childhood medulloblastoma. J Clin Oncol (2005) 2.34
Incidence and severity of postoperative cerebellar mutism syndrome in children with medulloblastoma: a prospective study by the Children's Oncology Group. J Neurosurg (2006) 2.31
Atypical teratoid/rhabdoid tumors (ATRT): improved survival in children 3 years of age and older with radiation therapy and high-dose alkylator-based chemotherapy. J Clin Oncol (2005) 2.19
Dysregulation of gene expression in the R6/2 model of polyglutamine disease: parallel changes in muscle and brain. Hum Mol Genet (2002) 2.17
A mouse model of the most aggressive subgroup of human medulloblastoma. Cancer Cell (2012) 2.15
Regulation of thalamocortical patterning and synaptic maturation by NeuroD2. Neuron (2006) 2.15
A feasibility trial of antiangiogenic (metronomic) chemotherapy in pediatric patients with recurrent or progressive cancer. J Pediatr Hematol Oncol (2005) 2.14
PTEN function in normal and neoplastic growth. Cancer Lett (2006) 2.10
Bone marrow recurrence after initial intensive treatment for childhood acute lymphoblastic leukemia. Cancer (2005) 1.93
Frequent amplification of a chr19q13.41 microRNA polycistron in aggressive primitive neuroectodermal brain tumors. Cancer Cell (2009) 1.92
Developmental model relating white matter volume to neurocognitive deficits in pediatric brain tumor survivors. Cancer (2003) 1.88
Amifostine protects against cisplatin-induced ototoxicity in children with average-risk medulloblastoma. J Clin Oncol (2008) 1.87
The Smo/Smo model: hedgehog-induced medulloblastoma with 90% incidence and leptomeningeal spread. Cancer Res (2008) 1.84
Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a Pediatric Brain Tumor Consortium report. Neuro Oncol (2007) 1.84
PIK3CA and PTEN mutations in uterine endometrioid carcinoma and complex atypical hyperplasia. Clin Cancer Res (2006) 1.83
Significance testing for small microarray experiments. Stat Med (2005) 1.80
Targeted therapy for BRAFV600E malignant astrocytoma. Clin Cancer Res (2011) 1.79